Title: Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is
associated with immunotherapy efficacy and survival in colorectal cancer
Version: 1 Date: 29 Jun 2022
Reviewer's report:
The authors have conducted a detailed database-based analysis of the relationship between
colorectal cancer SELENBP1 expression and the cancer microenvironment and have derived
solid results. The research is very clear and easy to understand.
1) The authors should include a clearer picture of Fig. 2b, which clearly shows that the expression
level of SELENBP1 is decreased in the tumor area.
2) For Fig. 2c-f, the authors show immunohistological staining of normal and tumor. Can you
show that the degree of SELENBP1 expression in tumors correlates with prognosis, based on
the results of immunohistological staining at your institution?
3) For Fig. 3b, if the AUC is less than 0.5, can you show the predictive endpoints in reverse?
4) It is a very important finding that SELENBP1 is associated with immune infiltration and
efficacy of immunotherapy. However,   what is shown in Fig. 9i alone is not a sufficient evidence
for a favorable antitumor effect of SELENBP1 expression on immune checkpoint inhibitors. We
do not question the overall results of the authors' study, but a figure should be included at the
end that supplements and reinforces the validity of the results presented in the database. Various
analyses have been performed, but as a result, there is a lack of new scientific knowledge for
the reader to gain.
Title: Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is
associated with immunotherapy efficacy and survival in colorectal cancer
Version: 1 Date: 29 Jun 2022
Reviewer's report:
The authors have conducted a detailed database-based analysis of the relationship between
colorectal cancer SELENBP1 expression and the cancer microenvironment and have derived
solid results. The research is very clear and easy to understand.
1) The authors should include a clearer picture of Fig. 2b, which clearly shows that the expression
level of SELENBP1 is decreased in the tumor area.
2) For Fig. 2c-f, the authors show immunohistological staining of normal and tumor. Can you
show that the degree of SELENBP1 expression in tumors correlates with prognosis, based on
the results of immunohistological staining at your institution?
3) For Fig. 3b, if the AUC is less than 0.5, can you show the predictive endpoints in reverse?
4) It is a very important finding that SELENBP1 is associated with immune infiltration and
efficacy of immunotherapy. However,   what is shown in Fig. 9i alone is not a sufficient evidence
for a favorable antitumor effect of SELENBP1 expression on immune checkpoint inhibitors. We
do not question the overall results of the authors' study, but a figure should be included at the
end that supplements and reinforces the validity of the results presented in the database. Various
analyses have been performed, but as a result, there is a lack of new scientific knowledge for
the reader to gain.
Please review this paper.
user
Title: Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is
associated with immunotherapy efficacy and survival in colorectal cancer
Version: 1 Date: 29 Jun 2022
Reviewer's report:
The authors have conducted a detailed database-based analysis of the relationship between
colorectal cancer SELENBP1 expression and the cancer microenvironment and have derived
solid results. The research is very clear and easy to understand.
1) The authors should include a clearer picture of Fig. 2b, which clearly shows that the expression
level of SELENBP1 is decreased in the tumor area.
2) For Fig. 2c-f, the authors show immunohistological staining of normal and tumor. Can you
show that the degree of SELENBP1 expression in tumors correlates with prognosis, based on
the results of immunohistological staining at your institution?
3) For Fig. 3b, if the AUC is less than 0.5, can you show the predictive endpoints in reverse?
4) It is a very important finding that SELENBP1 is associated with immune infiltration and
efficacy of immunotherapy. However,   what is shown in Fig. 9i alone is not a sufficient evidence
for a favorable antitumor effect of SELENBP1 expression on immune checkpoint inhibitors. We
do not question the overall results of the authors' study, but a figure should be included at the
end that supplements and reinforces the validity of the results presented in the database. Various
analyses have been performed, but as a result, there is a lack of new scientific knowledge for
the reader to gain.
assistant